Tech Xplore on MSN
Research drives commercialization of energy-efficient solar cell technology toward 40% efficiency milestone
Third-generation solar cell technology is advancing rapidly. An engineering research team at The Hong Kong Polytechnic ...
Solar energy plays a big role in the fight against climate change. As the world turns to solar power, concerns about the environmental impact of traditional solar panels continue to grow. Today’s most ...
Cell movement is an essential biological process, whether it's cancer cells metastasizing to other parts of the body or ...
A research team in South Korea has successfully developed a novel technology that combines nanoparticles with stem cells to ...
Epishine, a company producing solar cells optimised for indoor lighting, has announced its technology is being used in a new ...
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
Peripheral Blood Mononuclear Cells (PBMCs) are key immune cells separate from peripheral blood and crucial to the immune response. They identify and eliminate abnormal cells and foreign pathogens to ...
Honda will send its fuel-cell technology to the International Space Station to develop a closed-loop energy and sustainability system to support life in space and on the moon. “The project is part of ...
Ocata Therapeutics of Marlborough, which researches treatments for eye diseases, has agreed to be sold to Astellas Pharma Inc. of Japan for $379 million, the two companies announced late Monday.
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...
CytoMed Therapeutics Limited (NASDAQ: GDTC) ('CytoMed” or 'Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop ...
Losses at Advanced Cell Technology (ACT) of Marlborough deepened in its first quarter, as the cost of clinical trials for its macular degeneration treatments rose, the company said. Advanced Cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results